Inibição do ligante RANK para combater a sarcopenia com osteoporose subjacente
Inibição do ligante RANK para combater a sarcopenia com osteoporose subjacente: um ensaio randomizado, duplo-cego, duplo simulado e com controle ativo
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Aims:
- To assess whether receptor activator of nuclear factor-kB ligand (RANKL)-inhibition can treat sarcopenia in osteosarcopenic patients, in terms of appendicular skeletal muscle mass (ASM), handgrip strength, and physical performance.
- To assess whether RANKL-inhibition improves quality of life, and decreases falls, fractures, hospital admissions and mortality in osteosarcopenic patients.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Ronald Man Yeung Wong
- Número de telefone: 852 3505 1654
- E-mail: ronald.wong@cuhk.edu.hk
Locais de estudo
-
-
-
Hong Kong, China
- Recrutamento
- The Chinese University of Hong Kong
-
Contato:
- Ronald Man Yeung Wong
- Número de telefone: 852 3505 1654
- E-mail: ronald.wong@cuhk.edu.hk
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Elderly males or females aged 65 years or older
- diagnosed with osteosarcopenia (sarcopenia diagnosis based on AWGS 2019 guidelines - low appendicular skeletal muscle mass (ASM) by Dual-energy X-ray absorptiometry (DXA) (M:<7.0kg/m2, F:<5.4kg/m2) AND low handgrip strength (M:<28kg, F:<18kg) OR low physical performance (6-metre walk: <1.0m/s or 5-time chair stand test ≥ 12 s); osteoporosis diagnosed based on World Health Organization (WHO) criteria with DXA scan T-score ≤ -2.5)
- Willing and able to comply with study protocol including follow-up evaluations.
Exclusion Criteria:
- history of recent fracture i.e., within 3 months
- history of prior anti-osteoporotic drug
- disease or medication affecting bone or muscle metabolism
- Chairbound or bedbound
- Unable to agree for consent
- contraindication to drug i.e., Denosumab or Zoledronic Acid
- Underlying malignancy or disease known to cause cachexia
- severe renal impairment e.g., Creatinine Clearance (CrCl) < 35ml/min
- moderate to severe liver failure (Child-Pugh Class B or C).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Denosumab group
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly |
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly |
|
Comparador de Placebo: Zolendronic acid group
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months |
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
6-metre walk
Prazo: From enrollment to the end of treatment at 52 weeks
|
The time taken to walk 6 metres without deceleration. Average result of 2 trials is recorded. Slow speed is defined as &lt;1.0m/s. |
From enrollment to the end of treatment at 52 weeks
|
|
5-time chair stand test
Prazo: From enrollment to the end of treatment at 8 weeks
|
The time to rise from a chair 5 times is recorded. The cut-off for is taken at &gt;=12 seconds. |
From enrollment to the end of treatment at 8 weeks
|
|
Appendicular skeletal muscle mass (ASM)
Prazo: From enrollment to the end of treatment at 52 weeks
|
Determined with Dual-energy X-ray absorptiometry (Horizon®, DXA system, Hologic, USA). Total ASM by DXA is evaluated by segmented measurement of muscle mass at four limbs by operator-defined cutlines at specific anatomical landmarks. ASM is adjusted to square of height to calculate ASMI (kg/m2). Low ASMI by DXA is &lt; 7 kg/m2 for men and 5.4 kg/m2 for women. |
From enrollment to the end of treatment at 52 weeks
|
|
Handgrip strength
Prazo: From enrollment to the end of treatment at 52 weeks
|
Assessed by spring-type hand dynamometer (JAMAR Hand Dynamometer 5030JO). Cut-off for men is &lt; 28kg, and female is &lt;18kg. Maximum reading of 3 trials using dominant hand in a maximum-effort isometric contraction |
From enrollment to the end of treatment at 52 weeks
|
|
Quadriceps muscle strength
Prazo: From enrollment to the end of treatment at 52 weeks
|
Measured on affected limb with isometric dynamometer (Baseline, Genova, Italy). Subject will sit on a chair with both feet above ground, while raising the affected leg 45° forwards. The dynamometer is placed above the ankle and the subject will push the leg forward with maximum force. Measurements will be repeated 3 times and maximum value will be used for evaluation |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Prazo: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes directional control (%). |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Prazo: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes movement velocity (degrees/s) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Prazo: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes endpoint excursion (%) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Prazo: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes maximum excursion (%) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Prazo: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes reaction time(s) |
From enrollment to the end of treatment at 52 weeks
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Falls
Prazo: From enrollment to the end of treatment at 52 weeks
|
To assess the occurrence of falls, patients are required to self-report via a fall calendar, which will be returned at 1-year |
From enrollment to the end of treatment at 52 weeks
|
|
Fracture
Prazo: From enrollment to the end of treatment at 52 weeks
|
Assess occurrence of a fracture within a year of study period. |
From enrollment to the end of treatment at 52 weeks
|
|
Quality of life Short Form-36 (SF-36)
Prazo: From enrollment to the end of treatment at 52 weeks
|
The highest score is 900, and the lowest score is 0. Highest score indicates a better quality of life. |
From enrollment to the end of treatment at 52 weeks
|
|
Physical activity scale for elderly (PASE)
Prazo: From enrollment to the end of treatment at 52 weeks
|
It assesses the types of activities typically chosen by older adults, ranging from 0 to 793, with higher scores indicating greater physical activity |
From enrollment to the end of treatment at 52 weeks
|
|
Food frequency questionnaire
Prazo: From enrollment to the end of treatment at 52 weeks
|
Daily and weekly intake of 280 food items will be performed using a validated food frequency questionnaire developed in a local population survey. Mean nutrient quantitation and energy intake per day will be calculated referring to food composition tables derived from the Chinese Medical Sciences Institute and Centre for Food Safety in Hong Kong. |
From enrollment to the end of treatment at 52 weeks
|
|
Hospital admissions
Prazo: From enrollment to the end of treatment at 52 weeks
|
Number and cause of emergency hospital admission within 1 year of study period are documented. |
From enrollment to the end of treatment at 52 weeks
|
|
Mortality
Prazo: From enrollment to the end of treatment at 52 weeks
|
Mortality within 1-year of study period is documented. |
From enrollment to the end of treatment at 52 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2022.555
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .